Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes

HH Parving, BM Brenner, JJV McMurray, D de Zeeuw, SM Haffner, SD Solomon, N Chaturvedi, F Persson, AS Desai, M Nicolaides, A Richard, ZH Xiang, P Brunel, MA Pfeffer

Research output: Contribution to journalArticleAcademicpeer-review

977 Citations (Scopus)

Abstract

BACKGROUND This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both. METHODS In a double-blind fashion, we randomly assigned 8561 patients to aliskiren (300 mg daily) or placebo as an adjunct to an angiotensin-converting-enzyme inhibitor or an angiotensin-receptor blocker. The primary end point was a composite of the time to cardiovascular death or a first occurrence of cardiac arrest with resuscitation; nonfatal myocardial infarction; nonfatal stroke; unplanned hospitalization for heart failure; end-stage renal disease, death attributable to kidney failure, or the need RESULTS The trial was stopped prematurely after the second interim efficacy analysis. After a median follow-up of 32.9 months, the primary end point had occurred in 783 patients (18.3%) assigned to aliskiren as compared with 732 (17.1%) assigned to placebo (hazard ratio, 1.08; 95% confidence interval [CI], 0.98 to 1.20; P = 0.12). Effects on secondary renal end points were similar. Systolic and diastolic blood pressures were lower with aliskiren (between-group differences, 1.3 and 0.6 mm Hg, respectivel CONCLUSIONS The addition of aliskiren to standard therapy with renin-angiotensin system blockade in patients with type 2 diabetes who are at high risk for cardiovascular and renal events is not supported by these data and may even be harmful. (Funded by Novartis; ALTITUDE ClinicalTrials.gov number, NCT00549757.)
Original languageUndefined/Unknown
Pages (from-to)2204-2213
Number of pages10
JournalNew England Journal of Medicine
Volume367
Issue number23
DOIs
Publication statusPublished - 2012
Externally publishedYes

Cite this